ATE228113T1 - Acetamidderivate, verfahren zu ihrer herstellung und medizinische verbindungen diese enthaltend - Google Patents

Acetamidderivate, verfahren zu ihrer herstellung und medizinische verbindungen diese enthaltend

Info

Publication number
ATE228113T1
ATE228113T1 AT96909327T AT96909327T ATE228113T1 AT E228113 T1 ATE228113 T1 AT E228113T1 AT 96909327 T AT96909327 T AT 96909327T AT 96909327 T AT96909327 T AT 96909327T AT E228113 T1 ATE228113 T1 AT E228113T1
Authority
AT
Austria
Prior art keywords
production
compounds containing
containing same
medical compounds
acetamide derivatives
Prior art date
Application number
AT96909327T
Other languages
English (en)
Inventor
Teruya Murata
Katsuhiko Hino
Kiyoshi Furukawa
Makoto Oka
Mari Itoh
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Application granted granted Critical
Publication of ATE228113T1 publication Critical patent/ATE228113T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AT96909327T 1995-04-13 1996-04-10 Acetamidderivate, verfahren zu ihrer herstellung und medizinische verbindungen diese enthaltend ATE228113T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11393795 1995-04-13
PCT/JP1996/000977 WO1996032383A1 (en) 1995-04-13 1996-04-10 Acetamide derivatives, process for producing the same, and medicinal composition containing the same

Publications (1)

Publication Number Publication Date
ATE228113T1 true ATE228113T1 (de) 2002-12-15

Family

ID=14624947

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96909327T ATE228113T1 (de) 1995-04-13 1996-04-10 Acetamidderivate, verfahren zu ihrer herstellung und medizinische verbindungen diese enthaltend

Country Status (25)

Country Link
US (1) US5972946A (de)
EP (1) EP0826673B1 (de)
KR (1) KR100433589B1 (de)
CN (1) CN1094929C (de)
AR (1) AR002289A1 (de)
AT (1) ATE228113T1 (de)
AU (1) AU694647B2 (de)
BR (1) BR9604894A (de)
CA (1) CA2218033A1 (de)
CZ (1) CZ289093B6 (de)
DE (1) DE69624916T2 (de)
DK (1) DK0826673T3 (de)
ES (1) ES2187644T3 (de)
HU (1) HUP9801688A3 (de)
IL (1) IL117659A (de)
NO (1) NO310619B1 (de)
NZ (1) NZ304982A (de)
PL (1) PL322819A1 (de)
PT (1) PT826673E (de)
RO (1) RO117532B1 (de)
RU (1) RU2160256C2 (de)
SK (1) SK281840B6 (de)
TW (1) TW450963B (de)
WO (1) WO1996032383A1 (de)
ZA (1) ZA962438B (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT781766E (pt) * 1994-09-09 2004-07-30 Nippon Shinyaku Co Ltd Derivado heterociclico e medicamento
US6333358B1 (en) 1997-08-04 2001-12-25 Taisho Pharmaceutical Co., Ltd. Aryloxyaniline derivatives
EP1032377B1 (de) 1997-11-21 2010-11-17 Purdue Neuroscience Company Substituierte 2-aminoacetamide und anwendung davon
ZA9810490B (en) 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
WO1999058117A1 (fr) * 1998-05-13 1999-11-18 Sanofi-Synthelabo Utilisation de composes reduisant l'apoptose
FR2778564B1 (fr) * 1998-05-13 2001-07-13 Sanofi Sa Utilisation de composes reduisant l'apoptose
JP2002241369A (ja) * 1998-05-18 2002-08-28 Dainippon Pharmaceut Co Ltd ４−ピリミジニルアミノアセトアミド誘導体及びそれを含有する医薬組成物
DE19853278A1 (de) 1998-11-19 2000-05-25 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
ATE300947T1 (de) 1998-12-18 2005-08-15 Scios Inc Behandlung von erkrankungen mit zystenbildung
DE69932449T2 (de) 1998-12-18 2007-03-15 Scios Inc., Fremont Agonisten und antagonisten von benzodiazepinrezeptoren des peripheren typs
EP1607744A3 (de) * 1998-12-18 2009-09-30 Scios Inc. Behandlung von zystenbildenden Erkrankungen mit Kombinationen enthaltend PTBR-Agonisten
US6465513B1 (en) 1999-01-22 2002-10-15 Elan Pharmaceuticals, Inc. Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
HK1043794A1 (zh) * 1999-01-22 2002-09-27 依兰制药公司 抑制vla-4介导的白细胞粘附的稠合环杂芳基和杂环化合物
ATE455106T1 (de) * 1999-01-22 2010-01-15 Elan Pharm Inc Acyl derivate zur behandlung von krankheiten die in zusammenhang mit vla-4 stehen
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
DE19904710A1 (de) * 1999-02-05 2000-08-10 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-tetrahydrochinazoline, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
JP2002538135A (ja) 1999-03-01 2002-11-12 エラン ファーマシューティカルズ，インコーポレイテッド α４β７レセプターアンタゴニストとして有用なα−アミノ酢酸誘導体
US7037916B2 (en) 1999-07-15 2006-05-02 Pharmacopeia Drug Discovery, Inc. Pyrimidine derivatives as IL-8 receptor antagonists
WO2001036392A1 (en) * 1999-11-17 2001-05-25 Dainippon Pharmaceutical Co., Ltd. [5-chloro-6-phenyl-2-(4-trifluoromethylphenyl)-4-pyrimidinylamino]acetamide derivatives, process for producing the same, medicinal compositions containing the same and intermediate of these compounds
EP1233949A2 (de) * 2000-03-16 2002-08-28 Neurogen Corporation In 5-stellung substituierte arylpyrimidine
CA2416248A1 (en) 2000-07-18 2002-01-24 Neurogen Corporation 5-substituted 2-aryl-4-pyrimidinones
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
SI1318997T1 (sl) * 2000-09-15 2006-12-31 Vertex Pharma Pirazolne spojine, uporabne kot inhibitorji protein-kinaze
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ZA200301701B (en) * 2000-09-15 2004-03-01 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors.
RU2340611C2 (ru) * 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6989385B2 (en) * 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ATE466581T1 (de) 2001-12-07 2010-05-15 Vertex Pharma Verbindungen auf pyrimidin-basis als gsk-3-hemmer
WO2003066629A2 (en) * 2002-02-06 2003-08-14 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
MXPA04007026A (es) 2002-02-22 2004-10-11 Pharmacia & Up John Company Pirimidinonas y pirimidintionas sustituidas.
US20040009981A1 (en) * 2002-03-15 2004-01-15 David Bebbington Compositions useful as inhibitors of protein kinases
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200307671A (en) * 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
CN1319968C (zh) 2002-08-02 2007-06-06 沃泰克斯药物股份有限公司 用作gsk－3的抑制剂的吡唑组合物
JP4384053B2 (ja) * 2002-12-13 2009-12-16 エフ．ホフマン−ラ ロシュ アーゲー ３ｈ−キナゾリン−４−オン誘導体
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
US7601718B2 (en) * 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CN1894222A (zh) 2003-08-05 2007-01-10 沃泰克斯药物股份有限公司 作为电压门控离子通道抑制剂的稠合嘧啶化合物
US7378409B2 (en) * 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
US7592340B2 (en) * 2003-12-04 2009-09-22 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
CN1922141A (zh) * 2004-02-23 2007-02-28 大日本住友制药株式会社 新的杂环化合物
GT200600005A (es) * 2005-01-12 2006-08-16 Un derivado de 2-(aminocarbonilo ciclico)-indolina y una composicion farmaceutica que lo contiene
ATE542814T1 (de) * 2005-08-18 2012-02-15 Vertex Pharma Pyrazinkinaseinhibitoren
CA2624524C (en) * 2005-09-29 2014-07-08 Elan Pharmaceuticals, Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4
BRPI0616687A2 (pt) 2005-09-29 2011-06-28 Elan Pharm Inc compostos de pirimidinil amida que inibem a adesão leucocitária mediada por vla-4
MX2008005814A (es) * 2005-11-03 2008-10-15 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasa.
JP4955009B2 (ja) * 2005-11-11 2012-06-20 エフ．ホフマン−ラ ロシュ アーゲー 凝固因子Ｘａの阻害剤としての炭素環式縮合環アミン
CA2643838A1 (en) 2006-02-27 2007-09-07 Elan Pharmaceuticals, Inc. Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
WO2007110337A1 (en) * 2006-03-29 2007-10-04 F. Hoffmann-La Roche Ag Pyridine and pyrimidine derivatives as mglur2 antagonists
CA2668429A1 (en) * 2006-11-02 2008-05-15 Vertex Pharmaceuticals Incorporated Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
ES2347721T3 (es) * 2006-12-19 2010-11-03 Vertex Pharmaceuticals, Inc. Aminopirimidinas utiles como inhibidores de proteina quinasas.
EP1941879A1 (de) * 2007-01-05 2008-07-09 PAION Deutschland GmbH Nervenschutzmittel zur Behandlung von neuronalen Schäden.
EP2134709A1 (de) 2007-03-09 2009-12-23 Vertex Pharmaceuticals, Inc. Aminopyridine als proteinkinasehemmer
EP2137183B1 (de) * 2007-03-09 2011-09-28 Vertex Pharmaceuticals Incorporated Als inhibitoren von proteinkinasen geeignete aminopyrimidine
AU2008226457B2 (en) * 2007-03-09 2014-03-20 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
MX2009010127A (es) * 2007-03-22 2009-11-05 Vertex Pharma Compuestos utiles como inhibidores de janus cinasas.
NZ580343A (en) 2007-04-13 2012-03-30 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
CA2694381A1 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
MX2009011811A (es) * 2007-05-02 2010-01-14 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasa.
JP5389785B2 (ja) 2007-05-02 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用なチアゾールおよびピラゾール
EP2164842A2 (de) * 2007-05-24 2010-03-24 Vertex Pharmaceuticals Incorporated Als kinaseinhibitoren geeignete thiazole und pyrazole
NZ582879A (en) * 2007-07-31 2012-03-30 Vertex Pharma Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
NZ600238A (en) 2008-06-19 2014-04-30 Takeda Pharmaceutical Heterocyclic compound and use thereof
MX2011002312A (es) * 2008-09-03 2011-04-26 Vertex Pharma Co-cristales y formulaciones farmaceuticas que comprenden los mismos.
US8691866B2 (en) 2008-12-10 2014-04-08 The General Hospital Corporation HIF inhibitors and use thereof
WO2010126914A1 (en) * 2009-04-27 2010-11-04 Elan Pharmaceuticals, Inc. Pyridinone antagonists of alpha-4 integrins
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
JP2013032290A (ja) * 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
EP3323818A1 (de) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulatoren des gpr119-rezeptors und behandlung von damit assoziierten erkrankungen
KR20140003438A (ko) 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 항바이러스성 축합 헤테로사이클릭 화합물
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3631045A (en) * 1969-11-04 1971-12-28 American Home Prod 4 5-diamino-7h-pyrrolo(2 3-d)pyrimidine derivatives
US3631036A (en) * 1969-11-04 1971-12-28 American Home Prod 5-amino-2 6-substituted-7h-pyrrolo(2 3-d) pyrimidines and related compounds
FR2263750A1 (en) * 1974-03-12 1975-10-10 Delalande Sa N-phenyl-N-(2-aryl-6-methyl-pyrimidin-4-yl)amino acid derivs. - useful e.g. as analeptics, hypotensives, analgesics, etc.
FR2525595A1 (fr) * 1982-04-27 1983-10-28 Pharmuka Lab Nouveaux derives d'arene et d'heteroarenecarboxamides et leur utilisation comme medicaments
FR2582514B1 (fr) * 1985-05-30 1988-02-19 Rhone Poulenc Sante Medicaments a base d'amides, nouveaux amides et leur preparation
DK273689A (da) * 1988-06-06 1989-12-07 Sanofi Sa 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler
JPH07165721A (ja) * 1993-12-15 1995-06-27 Sumitomo Chem Co Ltd 放射性イソキノリンカルボキサミド誘導体

Also Published As

Publication number Publication date
CZ322397A3 (cs) 1998-02-18
SK281840B6 (sk) 2001-08-06
BR9604894A (pt) 1998-07-14
KR100433589B1 (ko) 2004-09-13
EP0826673A4 (de) 1998-09-02
DE69624916D1 (de) 2003-01-02
AU5287496A (en) 1996-10-30
HUP9801688A2 (hu) 1999-03-29
HUP9801688A3 (en) 2001-11-28
DE69624916T2 (de) 2003-04-24
IL117659A (en) 2000-12-06
ES2187644T3 (es) 2003-06-16
EP0826673B1 (de) 2002-11-20
WO1996032383A1 (en) 1996-10-17
AR002289A1 (es) 1998-03-11
CN1094929C (zh) 2002-11-27
AU694647B2 (en) 1998-07-23
DK0826673T3 (da) 2003-03-24
EP0826673A1 (de) 1998-03-04
KR19980703815A (ko) 1998-12-05
SK137497A3 (en) 1998-05-06
ZA962438B (en) 1996-10-01
CA2218033A1 (en) 1996-10-17
NZ304982A (en) 1999-03-29
RU2160256C2 (ru) 2000-12-10
NO974685D0 (no) 1997-10-10
RO117532B1 (ro) 2002-04-30
PL322819A1 (en) 1998-02-16
CN1186487A (zh) 1998-07-01
IL117659A0 (en) 1996-07-23
NO974685L (no) 1997-12-12
TW450963B (en) 2001-08-21
CZ289093B6 (cs) 2001-10-17
US5972946A (en) 1999-10-26
PT826673E (pt) 2003-02-28
NO310619B1 (no) 2001-07-30

Similar Documents

Publication Publication Date Title
ATE228113T1 (de) Acetamidderivate, verfahren zu ihrer herstellung und medizinische verbindungen diese enthaltend
ATE296823T1 (de) Substituierte heterocyclische verbindungen, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
ATE197801T1 (de) Benzazepin-, benzoxazepin- und benzothiazepin-n- essigsäure-derivate sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
ATE266673T1 (de) Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE59908522D1 (de) Benzothiepin-1,1-dioxidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
ATE222250T1 (de) Phenoxypropanolamin-derivate, verfahren zu ihrer herstellung und diese enthaltenden pharmazeutischen zusammensetzungen
ATE235507T1 (de) Neue aminosäurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
DE50111293D1 (de) Diphenylazetidinonderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
DE50110906D1 (de) Diphenylazetidinonderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
DE50114874D1 (de) Chinazolinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE59611204D1 (de) Arylglycinamidderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
ATE221531T1 (de) Kristallmodifikation des cdch, verfahren zu dessen herstellung und diese enthaltende pharmazeutische zubereitungen
ATE219069T1 (de) Neue arylglycinamidderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
DE59810127D1 (de) Bispyrazolazaverbindungen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Haarfärbemittel
DE69909209D1 (de) Pyrimidinon-derivate, diese verbindungen enthaltenden pharmazeutische zubereitungen und verfharen zu ihrer herstellung
ATE143010T1 (de) Pyridazin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
AT397797B (de) Capsaicin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
ATE211745T1 (de) 10,13,15-trioxatricyclo(9.2.1.1. 9.6)- pentadecanon-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE58905246D1 (de) Heterocyclische substituierte alkoxycumarine, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel.
DE3579000D1 (de) Imidazolylalkylguanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
DE59600453D1 (de) Zinnbadbodenstein, und Verfahren zu seiner Herstellung
DE69630873D1 (de) Propylen-1-penten copolymerisate, verfahren zu deren herstellung und zusammensetzungen diese enthaltend
ATE244246T1 (de) Pyridothienodiazepine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
DE69515341D1 (de) Diarylethylen-metallogenderivate, verfahren zu deren herstellung und diese enthaltende arzneizusammensetzungen
DE69628580D1 (de) Pestizide verbindungen, verfahren zu ihrer herstellung und zusammensetzungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0826673

Country of ref document: EP

REN Ceased due to non-payment of the annual fee